These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 20516123)
21. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations. Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123 [TBL] [Abstract][Full Text] [Related]
22. Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice. Figueiredo ML; Stein TJ; Jochem A; Sandgren EP Liver Int; 2012 Apr; 32(4):582-91. PubMed ID: 22221894 [TBL] [Abstract][Full Text] [Related]
23. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Fan HY; Liu Z; Paquet M; Wang J; Lydon JP; DeMayo FJ; Richards JS Cancer Res; 2009 Aug; 69(16):6463-72. PubMed ID: 19679546 [TBL] [Abstract][Full Text] [Related]
24. Comparison of liver oncogenic potential among human RAS isoforms. Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184 [TBL] [Abstract][Full Text] [Related]
25. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677 [TBL] [Abstract][Full Text] [Related]
26. Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway. Park YH; Kim SU; Kwon TH; Kim JM; Song IS; Shin HJ; Lee BK; Bang DH; Lee SJ; Lee DS; Chang KT; Kim BY; Yu DY Oncogene; 2016 Jul; 35(27):3503-13. PubMed ID: 26500057 [TBL] [Abstract][Full Text] [Related]
27. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma. Cho HC; Lai CY; Shao LE; Yu J Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965 [TBL] [Abstract][Full Text] [Related]
28. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant? Nussinov R; Tsai CJ; Jang H Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569 [TBL] [Abstract][Full Text] [Related]
29. Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Ohtani Y; Harada T; Funasaka Y; Nakao K; Takahara C; Abdel-Daim M; Sakai N; Saito N; Nishigori C; Aiba A Oncogene; 2008 Dec; 27(57):7162-70. PubMed ID: 18776920 [TBL] [Abstract][Full Text] [Related]
31. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598 [TBL] [Abstract][Full Text] [Related]
32. Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice. Yang G; Curley D; Bosenberg MW; Tsao H Cancer Res; 2007 Jun; 67(12):5649-57. PubMed ID: 17575131 [TBL] [Abstract][Full Text] [Related]
33. Three types of metaplasia model through Kras activation, Pten deletion, or Cdh1 deletion in the gastric epithelium. Kinoshita H; Hayakawa Y; Konishi M; Hata M; Tsuboi M; Hayata Y; Hikiba Y; Ihara S; Nakagawa H; Ikenoue T; Ushiku T; Fukayama M; Hirata Y; Koike K J Pathol; 2019 Jan; 247(1):35-47. PubMed ID: 30168144 [TBL] [Abstract][Full Text] [Related]
36. Unique dependence on Sos1 in You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195 [TBL] [Abstract][Full Text] [Related]
37. Critical role of oncogenic KRAS in pancreatic cancer (Review). Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414 [TBL] [Abstract][Full Text] [Related]
38. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Carrière C; Young AL; Gunn JR; Longnecker DS; Korc M Biochem Biophys Res Commun; 2009 May; 382(3):561-5. PubMed ID: 19292977 [TBL] [Abstract][Full Text] [Related]
39. BRAF and NRAS mutations in melanoma and melanocytic nevi. Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322 [TBL] [Abstract][Full Text] [Related]
40. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma. Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]